The ASC4START phase 3 trial aimed to assess asciminib vs. nilotinib tolerability in newly diagnosed Ph+ CML-CP adults. The primary endpoint was to determine the TTDAE. Patients are being treated along with multiple ongoing screenings. An anticipated 2–4.5 years for study completion. Asciminib, the pioneering BCR-ABL1 inhibitor designed to selectively target the ABL […]...
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Advertisement
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …
Objectives: Melanoma survival has greatly improved with the advent of immunotherapy, but unequal access to these medications may exist due to nonmedical patient factors such as insurance status, educational background, and geographic proximity to treatment. Methods: …
Objectives: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) promising in treating metastatic HER2+ and HER2-low breast cancer. This updated systematic review and meta-analysis, integrating data from the latest clinical trials, aimed to evaluate …
